Stock Events

Stock Events

Coherus Biosciences

$1.33

65

-$0.07-5.34% Friday 20:00

Statistics

Day High

1.39

Day Low

1.32

52W High

5.47

52W Low

1.32

Volume

1,486,010

Avg. Volume

1,691,193

Mkt Cap

152.59M

P/E Ratio

-2.37

Dividend Yield

-

Dividend

-

Earnings

9MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-0.96

-0.71

-0.46

-0.21

Expected EPS

-0.24

Actual EPS

-0.32

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CHRS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotech company that competes with Coherus in the biosimilars and biologics market, particularly in areas like oncology and inflammation.

Pfizer has a strong presence in the biosimilars market, directly competing with Coherus Biosciences in developing and marketing biosimilar versions of blockbuster drugs.

Syndax Pharmaceuticals

Syndax Pharmaceuticals is involved in developing therapies that could compete with Coherus's oncology portfolio, particularly in breast cancer treatments.

Merck competes with Coherus in the oncology sector, with a strong pipeline of cancer treatments that could rival Coherus's offerings.

Bristol-Myers Squibb

Bristol Myers Squibb has a diverse range of oncology products that compete with Coherus's cancer treatment portfolio.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries is a key player in the generic and biosimilar drugs market, making it a direct competitor to Coherus in several therapeutic areas.

AbbVie competes with Coherus in the biologics market, especially with their shared focus on autoimmune diseases and biosimilars.

Biogen's focus on innovative biologics in areas like neurology and autoimmune diseases puts it in competition with Coherus's biosimilar and novel biologic products.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biologics space, particularly in ophthalmology and rheumatology, areas where Coherus is also aiming to make an impact.

Novartis, through its generics division Sandoz, is a major player in the biosimilars market, competing directly with Coherus in offering lower-cost versions of biologic drugs.

Analyst Ratings

9$Average Price Target

The highest estimate is $12.

From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Biological Product (except Diagnostic) Manufacturing

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Show more...

CEO

Dennis Lanfear

Employees

249

Country

US

ISIN

US19249H1032

WKN

000A12ETZ

Listings